Eli Lilly’s Oxtoby Jumps to Aimmune for Chief Commercial Officer Post

Xconomy San Francisco — 

Aimmune Therapeutics (NASDAQ: AIMT) has appointed Andrew Oxtoby to serve as its chief commercial officer. Oxtoby comes to Brisbane, CA-based Aimmune after 16 years at Eli Lilly (NYSE: LLY), most recently as vice president of U.S. diabetes connected care and insulins. Aimmune is awaiting an FDA decision on its experimental peanut-allergy treatment, AR101.